An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

The most recent trading session ended with Astrazeneca (AZN) standing at $73.83, reflecting a +1.12% shift from the previouse ...

AstraZeneca (LSE:AZN) recently entered into a collaborative research initiative with IonQ, AWS, and NVIDIA, focused on ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

AstraZeneca’s rare disease business, Alexion, has partnered with British health tech Pangaea Data to fund the startup’s ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

Astrazeneca unveiled overhaul of its manufacturing and supply operations driven by deep tech and AI at London Tech Week.

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He ...

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...